Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to improve survival of patients with recurrent or metastatic
Adenoid Cystic Carcinoma (ACC). This study will test the efficacy of the investigational
drug, TKI258, in treating ACC.